<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Claire L Shovlin, PhD, FRCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lawrence LK Leung, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 25, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hereditary hemorrhagic telangiectasia (HHT; also called Osler-Weber-Rendu syndrome) is a vascular disorder inherited as an autosomal dominant trait, with a variety of clinical manifestations that vary between relatives who have the same HHT pathogenic gene variant.
        </p>
        <p>
         The most common problems are epistaxis, gastrointestinal bleeding, and iron deficiency anemia, along with characteristic mucocutaneous telangiectasia.
        </p>
        <p>
         In addition, arteriovenous malformations (AVMs) frequently affect the pulmonary, hepatic, and/or cerebral circulations, demanding knowledge of the risks and benefits of screening and treatment of patients with these complications.
        </p>
        <p>
         The pathophysiology, epidemiology, and diagnosis of HHT will be reviewed here. The management of HHT is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions"
         </a>
         .)
        </p>
        <p>
         Additional discussions of pulmonary AVMs, which affect over one-half of individuals with HHT, are also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8267.html" rel="external">
          "Pulmonary arteriovenous malformations: Epidemiology, etiology, and pathology in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8268.html" rel="external">
          "Pulmonary arteriovenous malformations: Clinical features and diagnostic evaluation in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">
          "Therapeutic approach to adult patients with pulmonary arteriovenous malformations"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H104272142">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epidemiologic studies suggest clinical prevalence rates between 1:5000 and 1:8000, with approximately 85,000 individuals affected in Europe [
         <a href="#rid1">
          1-6
         </a>
         ]. Much higher rates are described in certain geographically isolated populations (eg, 1:1330 in Afro-Caribbean residents of Curacao and Bonaire [
         <a href="#rid5">
          5
         </a>
         ]). The rate of diagnosis is lower in lower socioeconomic groups [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         The majority of patients are unaware of their diagnosis of HHT and have not been diagnosed at the time of hospital admission [
         <a href="#rid8">
          8
         </a>
         ]. As a result, HHT has been subject to under-reporting [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         HHT is inherited as an autosomal dominant trait with varying penetrance and expression.
        </p>
        <p>
         Pathogenic variants in multiple genes can cause HHT, with three major disease-associated genes [
         <a href="#rid9">
          9,10
         </a>
         ].
         <sup>
         </sup>
         As of 2022, 611 different HHT-causal variants are reported on the
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Farup.utah.edu%2Fdatabase%2FHHT%2F&amp;token=EhO1sIjRC%2BQY0lbH%2FIIl%2B6RI2dgjzAAgMCcP1rNIiIv1uS91N%2BFcn2yE%2Bi3fdKg7&amp;TOPIC_ID=1345" target="_blank">
          HHT mutation database
         </a>
         hosted by the University of Utah [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Of these, pathogenic variants are distributed as follows [
         <a href="#rid11">
          11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           ENG
          </em>
         </strong>
         <strong>
          (HHT1)
         </strong>
         – 333 of 611 (55 percent). These pathogenic variants cause loss-of-function in
         <em>
          ENG
         </em>
         (protein product:
         <strong>
          en
         </strong>
         do
         <strong>
          g
         </strong>
         lin, OMIM #187300).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           ACVRL1
          </em>
         </strong>
         <strong>
          (HHT2)
         </strong>
         – 263 (43 percent). These pathogenic variants cause loss-of-function in
         <em>
          ACVRL1
         </em>
         (protein product:
         <strong>
          ac
         </strong>
         ti
         <strong>
          v
         </strong>
         in
         <strong>
          r
         </strong>
         eceptor-
         <strong>
          l
         </strong>
         ike kinase 1, ALK1, OMIM #600376).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           SMAD4
          </em>
         </strong>
         <strong>
          (JPHT)
         </strong>
         – 15 (3 percent). JPHT is a juvenile polyposis-HHT overlap syndrome in which pathogenic variants cause loss-of-function in
         <em>
          SMAD4
         </em>
         (OMIM #175050) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Many additional pathogenic variants in these three HHT genes have been described, with none particularly common in different HHT families across the globe [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         More recently, homozygosity or heterozygosity for pathogenic variants in
         <em>
          GDF2
         </em>
         have been described as a rare cause of HHT [
         <a href="#rid14">
          14-16
         </a>
         ].
         <em>
          GDF2
         </em>
         encodes the ALK1/endoglin ligand bone morphogenetic protein (BMP)-9.
         <em>
         </em>
         It was previously recognized to cause HHT-like features [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
         These four genes all encode proteins involved in the BMP/transforming growth factor beta (TGF-beta) signaling pathway discussed further below. (See
         <a class="local">
          'Cellular changes'
         </a>
         below.)
        </p>
        <p>
         HHT is distinguished clinically and functionally from other vascular malformation syndromes resulting from pathogenic variants in mitogen-associated protein (MAP) kinase pathways. Heritable pathogenic variants in
         <em>
          RASA1
         </em>
         and
         <em>
          EPHB4
         </em>
         cause separate capillary malformation-arteriovenous malformation (CM-AVM) syndromes CM-AVM1 and CM-AVM2, respectively [
         <a href="#rid19">
          19-22
         </a>
         ]. Somatic variants leading to endothelial overactivation of MAP kinase pathways lead to a number of vascular malformation syndromes discussed separately.
        </p>
        <p class="headingAnchor" id="H197304">
         <span class="h2">
          Genotype-phenotype correlations and variable penetrance
         </span>
         <span class="headingEndMark">
          —
         </span>
         All classical features of HHT (nosebleeds; diagnostic mucocutaneous and gastrointestinal telangiectasia; pulmonary, hepatic, cerebral, and rare arteriovenous malformations [AVMs]) (see
         <a class="local">
          'Overview of clinical features'
         </a>
         below) can be seen in patients with HHT1, HHT2, and JPHT. (See
         <a class="local">
          'Genetics'
         </a>
         above.)
        </p>
        <p>
         Classical features of HHT are strongly predictive of a variant in
         <em>
          ENG
         </em>
         or
         <em>
          ACVRL1
         </em>
         [
         <a href="#rid23">
          23
         </a>
         ].
         <em>
         </em>
         Nevertheless, for this monogenic condition, there is marked individual variability, with advances in genetic understanding exposing the scale of reduced penetrance, and some of the contributors to phenotypic variability:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In keeping with other monogenic diseases, null alleles that define HHT do not imply that individual will necessarily develop particular clinical features of HHT [
         <a href="#rid24">
          24
         </a>
         ]. In a 2022 study of 152 unrelated adults in the United Kingdom with genetically confirmed HHT due to pathogenic variants in
         <em>
          ACVRL1
         </em>
         ,
         <em>
          ENG,
         </em>
         or
         <em>
          SMAD4
         </em>
         , only 104 (68 percent) met a clinical diagnosis of HHT [
         <a href="#rid25">
          25
         </a>
         ]. This group included 83 unrelated probands with one or more pulmonary AVMs and genetically-confirmed HHT; of these 83, 20 (24 percent) had few if any features of HHT [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It has been recognized for more than two decades that pulmonary and cerebral AVMs are more common in HHT1 patients, while hepatic AVMs, hepatic AVM-associated pulmonary hypertension, and pulmonary arterial hypertension (PAH) are more common in children and adults with HHT2 [
         <a href="#rid26">
          26-31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Variants in genes that increase the likelihood of developing pulmonary AVMs (in HHT1) and hepatic AVMs (in HHT2) are recognized [
         <a href="#rid32">
          32-34
         </a>
         ]. These include hypomorphic variants in the remaining dise
         <em>
          a
         </em>
         se
         <em>
         </em>
         allele from the unaffected parent [
         <a href="#rid33">
          33
         </a>
         ]. Variants in other genes have been implicated, potentially inherited from either parent, particularly protein tyrosine phosphatase non-receptor type
         <em>
          14 PTPN14
         </em>
         and a disintegrin and metalloprotease 1
         <em>
          7 (ADAM17
         </em>
         ) for pulmonary AVMs in HHT1 [
         <a href="#rid32">
          32,35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There have been no clear data that HHT bleeding differs between molecular HHT subtypes. Instead, new data suggest that HHT bleeding is more severe if there is chance coinheritance of a deleterious DNA variant in one of 35 coagulation and platelet genes that cause bleeding disorders in the general population [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These variants affecting hemostasis are very common in the general population. In 104 patients with HHT undergoing whole genome sequencing, predicted loss of function variants in platelet genes were found in 10 percent of patients (1 in 10), and loss of function variants in coagulation genes were found in 12.5 percent (1 in 8) [
         <a href="#rid36">
          36
         </a>
         ]. Further, in blinded analyses, HHT patients with more severe hemorrhage were more likely to have a deleterious variant in a platelet gene or coagulation gene [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When the individual is the first affected ("founder") member of the family, mosaicism may be present [
         <a href="#rid37">
          37-39
         </a>
         ]. This can pose challenges for molecular testing [
         <a href="#rid37">
          37-41
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         It is believed that most, if not all, cases of HHT result from haploinsufficiency (lack of sufficient protein for normal function) for endoglin (encoded by
         <em>
          ENG
         </em>
         ) or ALK1 (encoded by
         <em>
          ACVRL1
         </em>
         ); the most consistent mechanism is via generation of a premature termination codon resulting in nonsense-mediated decay of the abnormal messenger RNA (mRNA) transcript [
         <a href="#rid42">
          42
         </a>
         ]. There is ongoing debate regarding whether vascular malformations result from local loss of endoglin/ALK1 expression, with newer evidence pointing to somatic loss of the second allele in lesions [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         The University of Utah hosts the
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Farup.utah.edu%2Fdatabase%2FHHT%2F&amp;token=EhO1sIjRC%2BQY0lbH%2FIIl%2B6RI2dgjzAAgMCcP1rNIiIv1uS91N%2BFcn2yE%2Bi3fdKg7&amp;TOPIC_ID=1345" target="_blank">
          HHT mutation database
         </a>
         [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24973965">
         <span class="h2">
          Cellular changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         The HHT genes (
         <em>
          ENG
         </em>
         ,
         <em>
          ACVRL1
         </em>
         ,
         <em>
          SMAD4
         </em>
         and
         <em>
          GDF2
         </em>
         ) all encode proteins involved in the bone morphogenetic protein (BMP) signaling pathway, which is required for the development and maintenance of arteriovenous identity. Disruption of their function perturbs vascular remodeling and disrupts blood vessel wall integrity.
        </p>
        <p>
         Endoglin, ALK1 and Smad4 proteins modulate signaling by the BMP/transforming growth factor beta (TGFβ) superfamily, ligands for which include BMP2, TGF-betas, activins, and inhibins. Endoglin and ALK1 are transmembrane glycoproteins expressed abundantly on vascular endothelial cells. ALK1 is a type I receptor for the superfamily; endoglin associates with different superfamily receptor complexes (and with ALK1, a receptor complex for BMP9 [
         <a href="#rid44">
          44
         </a>
         ]). Smad4 acts downstream of these receptors in signal transduction cascades.
        </p>
        <p>
         In most cell types, TGF-beta 1 signaling via the type II receptor (TbetaRII) is propagated through ALK5 (TbetaRI), although in endothelial cells, TbetaRII signaling can also be propagated through ALK1 [
         <a href="#rid45">
          45
         </a>
         ]. Endoglin can modify TGF-beta-1 signaling, but with the discovery of specific ligands for ALK1, attention has also focused on BMP ligands BMP9 and BMP10 [
         <a href="#rid46">
          46
         </a>
         ]. BMP9 is of particular interest, where the endoglin-BMP9 interaction has been defined and clinical evidence has emerged [
         <a href="#rid14">
          14,17,44
         </a>
         ].
        </p>
        <p>
         The pure pulmonary artery hypertension (PAH) phenotype seen in patients with HHT is indistinguishable from primary PAH in the general population, caused by pathogenic DNA sequence variants in
         <em>
          BMPR2
         </em>
         , which encodes the BMPRII protein that also associates with ALK1, and where
         <em>
          GDF2
         </em>
         (encoding BMP9) has also been identified as disease causal. (See
         <a class="local">
          'Genotype-phenotype correlations and variable penetrance'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8247.html" rel="external">
          "The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)", section on 'Genetic mutations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2524536">
         <span class="h2">
          Vascular lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with HHT can have vascular lesions in a variety of vascular beds, and the lesions can include arteriovenous shunts (eg, AVMs/arteriovenous fistulae [AVFs]) and telangiectasia.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arteriovenous shunts
         </strong>
         – An arteriovenous shunt is a direct communication between arteries and veins. In anatomic shunts, abnormal vessels replace the normal capillary bed. These may be sacs (eg, for pulmonary AVMs), small collections of intervening vessels (nidal AVMs), or direct high-flow connection between the arterial and venous side (AVFs).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Telangiectasia
         </strong>
         – A telangiectasia is a small, dilated blood vessel (arteriole, venule, or capillary) that is apparent near the surface of skin or mucous membranes.
        </p>
        <p>
        </p>
        <p>
         These lesions can also be seen in other disorders besides HHT, or in otherwise healthy individuals, as part of a syndrome or in isolation. Additional vascular lesions are increasingly recognized, some seen more commonly in patients with HHT, and others, such as aneurysms, present at rates similar to the general population [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Differing disease patterns in members of the same family, as well as in mouse models, suggest that other genetic and environmental influences modify the HHT phenotype, and modifier genes are now described as above [
         <a href="#rid32">
          32-34,36
         </a>
         ]. (See
         <a class="local">
          'Genotype-phenotype correlations and variable penetrance'
         </a>
         above.)
        </p>
        <p>
         Why AVMs develop in particular vascular beds and not others remains unclear and is the subject of ongoing research. One possibility that has supporting evidence in some examined lesions suggests that somatic loss of the second allele occurs in some lesions, noting that in the limited AVM data, there is evidence of persistent expression of the second allele [
         <a href="#rid43">
          43,48
         </a>
         ].
        </p>
        <p>
         Several animal models of HHT have been described. Null mice for
         <em>
          ENG
         </em>
         and
         <em>
          ACVRL1
         </em>
         die between embryonic day 10.5 to 11.5 because of gross vascular and cardiac defects [
         <a href="#rid49">
          49
         </a>
         ]. Heterozygous mice develop variable but more HHT-specific features including nosebleeds, telangiectasia, dilated vessels, and AVMs [
         <a href="#rid50">
          50,51
         </a>
         ]. Conditional LoxP knockout alleles for all three HHT genes and for ALK1 have been created; in animal models, they cause HHT-like vascular malformations to occur in a consistent and predictable manner [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         There is substantial interest in roles of vascular endothelial growth factor (VEGF) in HHT. Increased plasma levels of VEGF and TGF-beta-1 have been seen in HHT patients [
         <a href="#rid53">
          53,54
         </a>
         ]. Furthermore, treatment with angiogenesis inhibitors has some efficacy in treating HHT. (See
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions", section on 'Bevacizumab and other systemic antiangiogenic therapies'
         </a>
         .)
        </p>
        <p>
         It is unclear whether VEGF is involved directly in the pathogenesis of what has been recognized as a BMP/TGF-beta superfamily disease, or whether these observations reflect the role of angiogenesis as a "second hit" phenomenon in HHT [
         <a href="#rid33">
          33,55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H615291">
         <span class="h2">
          Overview of clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         The combination of epistaxis, gastrointestinal bleeding, and iron deficiency anemia associated with characteristic telangiectasia on the lips, oral mucosa, and fingertips (
         <a class="graphic graphic_picture graphicRef77416" href="/z/d/graphic/77416.html" rel="external">
          picture 1
         </a>
         ) has become firmly established as a medical entity. All three areas were addressed within the Second International Guidelines [
         <a href="#rid56">
          56
         </a>
         ]; they are prominent in new tools to evaluate quality of life in HHT [
         <a href="#rid57">
          57,58
         </a>
         ].
        </p>
        <p>
         The classical constellation of findings underestimates potentially life-threatening aspects of HHT. In major series to date, at least one-half of HHT patients have pulmonary arteriovenous malformations (PAVMs), placing them at risk of early onset, preventable strokes; cerebral abscess; and other complications [
         <a href="#rid59">
          59-61
         </a>
         ]. Similarly hepatic AVMs affect approximately one-half of HHT patients and there is increasing concern about their implications, leading to a focus for the Second International Guidelines [
         <a href="#rid56">
          56
         </a>
         ]. Approximately 10 percent have cerebral involvement [
         <a href="#rid59">
          59,62,63
         </a>
         ] with varying vascular abnormalities [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Separate sets of considerations apply in pregnancy and pediatrics; these areas are also addressed.
        </p>
        <p>
         Individuals with HHT present to a wide range of clinicians spanning medical, surgical, general practice disciplines, and emergency departments, most of whom lack appreciation of the full range of consequences of the diagnosis of HHT for patients and their families [
         <a href="#rid64">
          64
         </a>
         ]. Separate Consensus Frameworks have been generated by the European Reference Network, VASCERN, to assist general clinicians as they encounter people with HHT during a standard consultation, and separately, HHT specialists [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         Most patients with HHT experience only epistaxis, mucocutaneous telangiectasia, and a tendency to develop iron deficiency anemia secondary to blood loss [
         <a href="#rid6">
          6,13,66,67
         </a>
         ]. However, some patients can have substantial symptoms, particularly attributable to severe recurrent nosebleeds and/or gastrointestinal bleeding, resulting in transfusion dependence, augmented when visceral arteriovenous malformations (AVMs) are present with resultant higher cardiac outputs.
        </p>
        <p>
         Visceral AVMs are usually silent, but they can cause major pathology (see
         <a class="local">
          'Sites of large arteriovenous malformations'
         </a>
         below):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PAVMs allow systemic venous blood to bypass the normal pulmonary circulation, resulting in paradoxical embolic stroke, brain abscess, migraines, and other complications; hemorrhage is rare except in pregnancy when it occurs at a rate of approximately 1 percent (
         <a class="graphic graphic_diagnosticimage graphicRef63662" href="/z/d/graphic/63662.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_table graphicRef74593" href="/z/d/graphic/74593.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="local">
          'Pulmonary AVMs'
         </a>
         below). Although PAVMs differ in size and complexity of vascular supply, all present the risk of continuous right-to-left shunting, determined by the proportion of the cardiac output flowing through the AVMs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cerebral vascular malformations in HHT are more diverse and span a range of vascular abnormalities with varying risks of hemorrhage, from minimal risk (eg, benign developmental venous anomalies, capillary malformations [sometimes inappropriately referred to as micro-AVMs], and cavernous malformations), to greater risk of hemorrhage (nidal AVMs) and significant risk of hemorrhage (AV fistulae [AVFs]) [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="local">
          'Cerebral vascular abnormalities'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatic AVMs can result in high-output cardiac failure or other pathologies, and are increasingly recognized as causing significant morbidity, requiring careful management and timely interventions. (See
         <a class="local">
          'Hepatic involvement'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         The majority of children in HHT families are troubled only by epistaxis, but there are children who become symptomatic due to AVMs, and issues are discussed further within the Second International Guidelines and European consensus statement [
         <a href="#rid47">
          47,68
         </a>
         ]. As noted above, most, if not all, AVMs may be present in childhood. In a series of 44 children screened in a multidisciplinary HHT center, 52 percent had hepatic AVMs, 45 percent had PAVMs, and 16 percent had cerebral AVMs [
         <a href="#rid69">
          69
         </a>
         ]. (See
         <a class="local">
          'Onset of disease manifestations'
         </a>
         below.)
        </p>
        <p>
         Despite the evident morbidity and mortality associated with HHT, life expectancy is surprisingly good, particularly in older individuals and in more recent series. Possible explanations are provided by relative protection from certain cancers, as might be predicted from the anticancer efficacy of antibodies that mimic the molecular basis of HHT (see
         <a class="local">
          'Cancer frequency'
         </a>
         below) and reduced rates of myocardial infarction [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18820894">
         <span class="h2">
          Onset of disease manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         HHT telangiectasia are not generally present at birth; they develop with increasing age. Screening programs that use imaging rather than clinical assessment identify AVMs earlier than the classical age-related prevalence studies, which were based on clinical signs; in the imaging-based studies, approximately 70 percent of individuals developed some clinical sign of HHT by the age of 16 years, rising to over 90 percent by the age of 40 years. The following describe the findings from these more intensive screening programs:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Epistaxis is usually the earliest sign of disease, often occurring in childhood.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mucocutaneous and gastrointestinal telangiectasia develop progressively with age [
         <a href="#rid67">
          67,71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PAVMs generally become apparent after puberty, although they may be present during childhood, and a computed tomography (CT)-based screening program indicated similar incidences in 74 children and 476 adults with HHT [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age of development of cerebral vascular malformations appears to depend on type, with most thought to have developed during childhood [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         There are specific circumstances in which HHT pathologies become more hazardous, the most important of which is pregnancy, which results in a 1 percent risk of maternal death per pregnancy (due to PAVM hemorrhage, cerebral hemorrhage, and thrombotic complications), with all published maternal deaths occurring in women previously considered well. (See
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions", section on 'Pregnancy'
         </a>
         .)
        </p>
        <p>
         There is also significant morbidity and mortality in younger patients, predominantly attributed to the consequences of visceral AVMs, especially pulmonary, cerebral, and hepatic AVMs; pulmonary hypertension; and venous thromboembolism (VTE). (See
         <a class="local">
          'Pulmonary hypertension'
         </a>
         below and
         <a class="local">
          'Venous thromboembolism'
         </a>
         below.)
        </p>
        <p>
         Many of these risks were quantified by a prospective 30-year follow-up series in Denmark [
         <a href="#rid3">
          3
         </a>
         ] and a retrospective study of the parents of 74 Italian patients with HHT [
         <a href="#rid74">
          74
         </a>
         ]. Even in these long retrospective series, for patients who did not present spontaneously to a clinician before the age of 60 years, there was no excess mortality [
         <a href="#rid3">
          3
         </a>
         ]. A subsequent 20-year follow-up series from Denmark indicated that life expectancy can be normalized for patients whose epistaxis, anemia, and PAVMs are expertly managed [
         <a href="#rid75">
          75
         </a>
         ]. This finding was confirmed by a second study in Europe [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Epistaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common clinical manifestation of HHT is spontaneous, recurrent epistaxis from telangiectasia of the nasal mucosa. Some patients experience no or minimal occasional episodes, but for the majority, recurrent and frequent epistaxis is a feature, with many patients experiencing daily bleeds. In an online survey of 666 patients with HHT, 649 (97 percent) reported nosebleeds, and 326 (49 percent) reported the use of specialist invasive treatments for epistaxis, most requiring multiple different modalities [
         <a href="#rid77">
          77
         </a>
         ]. In another study of 220 patients with HHT, nearly one-half reported nosebleeds occurring daily, and three-quarters reported nosebleeds at least once a week [
         <a href="#rid78">
          78
         </a>
         ]. A summary of additional studies is provided within the Second HHT International Guidelines [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         Epistaxis may be provoked by a variety of factors, such as changes in external temperature, humidity, activity, and posture. Additional data also highlight the possibility of dietary aggravation of nosebleeds in patients with HHT (eg, from alcohol, spices, high-salicylate dietary items, and migraine-precipitating foods) [
         <a href="#rid77">
          77,78
         </a>
         ].
        </p>
        <p>
         Patients can present with hemodynamic disturbance secondary to acute blood loss, particularly for patients describing arterial bleeds (ie, gushing nosebleeds in the epistaxis severity score) [
         <a href="#rid79">
          79,80
         </a>
         ].
        </p>
        <p>
         Management and prevention of epistaxis can range from mild interventions, such as nasal humidification, to
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         (which is effective but carries potential side effects), to more aggressive measures, depending on the severity of bleeding. Ablative therapies are recommended before considering systemic antiangiogenic therapy, with septodermoplasty and Young's procedure to close the nostrils also recommended for the most severe cases, as discussed in the Second HHT International Guidelines [
         <a href="#rid56">
          56
         </a>
         ]. Iron supplementation is commonly needed, and blood transfusions may be required. These subjects are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions", section on 'Epistaxis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/265.html" rel="external">
          "Approach to the adult with epistaxis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6484.html" rel="external">
          "Management of epistaxis in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Gastrointestinal bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent gastrointestinal bleeding occurs in up to one-third of patients with HHT, often presenting as iron deficiency anemia or an acute gastrointestinal bleeding episode, most commonly in patients over the age of 40 years [
         <a href="#rid71">
          71,81
         </a>
         ]. Gastrointestinal bleeding probably contributes less frequently to iron deficiency than under-recognized epistaxis. In many patients, improvement in nasal hemorrhage is able to significantly reduce iron and transfusion requirements. (See
         <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs", section on 'Iron status'
         </a>
         .)
        </p>
        <p>
         Telangiectasia can occur throughout the gastrointestinal tract and are more common in the stomach or duodenum than in the colon (
         <a class="graphic graphic_picture graphicRef50137 graphicRef73541" href="/z/d/graphic/50137.html" rel="external">
          picture 2A-B
         </a>
         ). They are visualized by endoscopy, are similar in size and appearance to mucocutaneous telangiectasia, and may be surrounded by an anemic halo. Less commonly, AVMs and aneurysms occur; these lesions may be visualized on angiographic studies of the gastrointestinal tract (
         <a class="graphic graphic_diagnosticimage graphicRef52754" href="/z/d/graphic/52754.html" rel="external">
          image 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2557.html" rel="external">
          "Angiodysplasia of the gastrointestinal tract"
         </a>
         .)
        </p>
        <p>
         Recommendations for management from the HHT International Guidelines are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions", section on 'Therapy for specific vascular lesions and iron deficiency'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Mucocutaneous telangiectasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Telangiectasia of the skin and buccal mucosa are present in most individuals in later life but may be absent or subtle when younger [
         <a href="#rid71">
          71
         </a>
         ]. They mostly occur on the lips, tongue, buccal mucosa, and fingertips, but can occur elsewhere, where they are less HHT specific and therefore not used for diagnostic purposes (
         <a class="graphic graphic_picture graphicRef77416" href="/z/d/graphic/77416.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef52483" href="/z/d/graphic/52483.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid82">
          82
         </a>
         ]. Bleeding can occur but is rarely clinically important.
        </p>
        <p class="headingAnchor" id="H20480786">
         <span class="h2">
          Sites of large arteriovenous malformations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically important AVMs can occur in a number of organs, such as the lung, brain, and liver. While single AVMs can occur sporadically in the normal population as well as in patients with HHT, the presence of multiple AVMs in an organ such as the lung or brain make a sporadic etiology less likely [
         <a href="#rid8">
          8,83
         </a>
         ]. However, single AVMs are still strongly associated with HHT in both organs. Additionally, CT-based research screening programs of asymptomatic individuals have identified pancreatic AVMs at surprisingly high frequency [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Pulmonary AVMs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary arteriovenous malformations (PAVMs) are abnormal vessels that replace normal capillaries between the pulmonary arterial and venous circulations, often resulting in bulbous sac-like structures (
         <a class="graphic graphic_diagnosticimage graphicRef56072" href="/z/d/graphic/56072.html" rel="external">
          image 3
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef54651" href="/z/d/graphic/54651.html" rel="external">
          image 4
         </a>
         ). They provide a direct capillary-free communication between the pulmonary and systemic circulations.
        </p>
        <p>
         Patients with PAVMs are at risk for complications, most commonly neurologic sequelae due to paradoxical embolism, with embolic material evading the filtering function of the pulmonary capillaries and reaching the central nervous system.
        </p>
        <p>
         The clinical features, diagnosis, and epidemiology of PAVMs are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8268.html" rel="external">
          "Pulmonary arteriovenous malformations: Clinical features and diagnostic evaluation in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8267.html" rel="external">
          "Pulmonary arteriovenous malformations: Epidemiology, etiology, and pathology in adults"
         </a>
         .)
        </p>
        <p>
         Management of PAVMs is also presented in detail separately, including screening, embolization, and the use of prophylactic antibiotics to reduce the role of brain abscess. (See
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions", section on 'Pulmonary AVMs'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">
          "Therapeutic approach to adult patients with pulmonary arteriovenous malformations"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4047611910">
         <span class="h4">
          Hypoxia and respiratory symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary arterial blood passing through these right-to-left shunts cannot be oxygenated, leading to hypoxemia. Hypoxemia results in an erythrocytotic stimulus, which can lead to clinically significant levels of secondary polycythemia.
        </p>
        <p>
         However, the majority of patients with PAVMs have no respiratory symptoms, and most are unaware that they have HHT or PAVMs [
         <a href="#rid8">
          8,85
         </a>
         ]. In one review, fewer than one-third of affected individuals exhibited physical signs indicating a substantial right-to-left shunt, such as cyanosis, clubbing, and/or polycythemia (
         <a class="graphic graphic_table graphicRef54074" href="/z/d/graphic/54074.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid86">
          86
         </a>
         ]. These proportions are likely to fall still further as more patients are diagnosed with more sensitive screening programs.
        </p>
        <p>
         When symptoms such as reduced exercise capacity occur, this generally reflects low hemoglobin and/or airflow limitation rather than hypoxemia [
         <a href="#rid87">
          87,88
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2829158025">
         <span class="h4">
          Cerebral embolic events (ischemic stroke and brain abscess) and bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Catastrophic embolic cerebral events (embolic stroke, transient ischemic attack, and brain abscess) occur in patients with clinically silent PAVMs and carry significant morbidity and mortality, indicating the need for early diagnosis and intervention, including embolization of PAVMs and antibiotic prophylaxis for interventional procedures, especially dental [
         <a href="#rid8">
          8,89
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ischemic stroke
         </strong>
         – The burden of ischemic stroke due to paradoxical embolism is summarized in a 2022 review [
         <a href="#rid90">
          90
         </a>
         ]. A study of 497 consecutive patients with CT-proven PAVMs found that 61 (12 percent) had acute, noniatrogenic ischemic stroke at a median age of 52 years [
         <a href="#rid91">
          91
         </a>
         ]. Additionally, the first nationwide analysis of 4,271,010 patients with ischemic stroke found that 822 had a PAVM diagnosis, with strokes occurring a decade earlier than stroke in patients without PAVMs [
         <a href="#rid92">
          92
         </a>
         ]. Other studies have documented that ischemic stroke precedes the diagnosis of HHT [
         <a href="#rid8">
          8
         </a>
         ]. As recently reviewed, the burden of silent cerebral infarction in patients with PAVMs is considerably higher than that of clinical stroke, with evidence of silent cerebral infarction by magnetic resonance imaging (MRI) in nearly 50 percent of individuals with PAVMs by 50 years of age [
         <a href="#rid63">
          63,90,93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Brain abscess
         </strong>
         – In a 2017 study of 445 consecutive adults with HHT and CT-confirmed PAVMs, 37 (8.3 percent) had brain abscesses [
         <a href="#rid94">
          94
         </a>
         ]. By multivariate logistic regression, brain abscess was associated with low oxygen saturation (indicated greater right-to-left shunt), higher transferrin saturation, intravenous use of iron for anemia, male sex, and venous thromboemboli. There were no relationships between the anatomic attributes of PAVMs and the likelihood of brain abscess. (See
         <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">
          "Therapeutic approach to adult patients with pulmonary arteriovenous malformations", section on 'Natural history'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions", section on 'Pulmonary AVMs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Very occasionally, PAVMs may bleed; this event is rare unless PAVMs have developed a systemic arterial supply (spontaneously or posttreatment), the individual is pregnant, or the individual has pulmonary hypertension. PAVM hemorrhage may lead to hemoptysis or hemothorax. Hemorrhage may occur from the fragile PAVM vessels into a bronchus or the pleural cavity, causing hemoptysis or hemothorax, respectively. However, this is rare outside of pregnancy [
         <a href="#rid8">
          8,95
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions", section on 'Pregnancy'
         </a>
         .)
        </p>
        <p>
         Patients with PAVMs have an increased prevalence of migraine [
         <a href="#rid96">
          96
         </a>
         ]; migraine may be precipitated by intravenous injections for CT imaging [
         <a href="#rid97">
          97
         </a>
         ]. Migraine symptoms may be reduced after embolization of PAVMs [
         <a href="#rid98">
          98
         </a>
         ]. (See
         <a class="local">
          'Migraines'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Cerebral vascular abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HHT may have cerebral or spinal cord involvement. Cerebrovascular malformations range from benign developmental venous anomalies, through capillary malformations (sometimes inappropriately referred to as micro-AVMs) and cavernous malformations, all with a low hemorrhagic risk, to classical nidal AVMs and high-flow cerebral arteriovenous fistulae (CAVFs; generally found in children) [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         As detailed in a position statement from the European Reference Network for Rare Vascular Diseases (VASCERN), the clinical presentations and prognosis depend on the type and location of the lesion [
         <a href="#rid47">
          47
         </a>
         ]. Other vascular and nonvascular pathology can occur as in the general population, and these appear to include aneurysms at no greater frequency than in the general population (
         <a class="graphic graphic_diagnosticimage graphicRef75190" href="/z/d/graphic/75190.html" rel="external">
          image 5
         </a>
         ) [
         <a href="#rid73">
          73,99
         </a>
         ].
        </p>
        <p>
         Cerebral vascular malformations affect approximately 10 percent of HHT patients, are often multiple, and are usually silent [
         <a href="#rid59">
          59,62,83,100
         </a>
         ]. They can affect children, when the risks are considerably higher due to the higher prevalence of CAVFs [
         <a href="#rid47">
          47
         </a>
         ]. While full screening across large populations of children in HHT families has not been undertaken, in one cohort of 52 children with HHT referred to neurologic services, neuroimaging at a median age of 5.2 years revealed cerebrovascular malformations in 14 (27 percent), with three developing new lesions over time. Unusually for the broader groups of HHT children, this cohort was highly symptomatic: three had an intracerebral hemorrhage (age of presentation, four to eight years) and another three had ischemic stroke or transient ischemic attack.
        </p>
        <p>
         The most dangerous lesions in HHT are cerebral AVFs, which predominantly affect children. High-flow shunts through AVFs in young infants can present with systemic circulatory overload or hydrovenous dysfunction (eg, macrocephaly, hydrocephalus). Other presentations include seizures, ischemia of the surrounding tissue due to a steal effect, or hemorrhage. Hemorrhage may be less frequent than that seen in non-HHT cerebral AVMs, in part due to the lower frequency of associated aneurysms. (See
         <a class="medical medical_review" href="/z/d/html/1129.html" rel="external">
          "Vascular malformations of the central nervous system", section on 'Capillary telangiectasias'
         </a>
         .)
        </p>
        <p>
         Cerebral hemorrhage often has devastating effects. Thus, patients with symptoms suggestive of cerebral AVMs (eg, unexplained headache or neurologic symptoms) deserve further assessment as in the non-HHT population, including noninvasive imaging and ultimately assessment by experienced neurointerventional centers. (See
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions", section on 'Cerebral lesions'
         </a>
         .)
        </p>
        <p>
         For patients without symptoms, the situation is more nuanced and carefully expressed in a recent statement led by European Neurointerventionalists [
         <a href="#rid47">
          47
         </a>
         ]. In the expert European centers, screening discussions are conducted with all families in an informed and personalized way to help all make the appropriate choice [
         <a href="#rid47">
          47
         </a>
         ]. This is important because it is not clear that invasive interventions for incidentally discovered cerebral AVMs are appropriate. Since the 2014 publication of the ARUBA trial, which demonstrated an increased risk of bleeding with treatment of asymptomatic cerebral AVMs, many more countries restrict screening to symptomatic patients or only perform screens after pretest counseling of patients [
         <a href="#rid101">
          101
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions", section on 'Cerebral lesions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs", section on 'Cerebral AVM screening'
         </a>
         .)
        </p>
        <p>
         Brain MRI is the most sensitive noninvasive test (
         <a class="graphic graphic_diagnosticimage graphicRef53992" href="/z/d/graphic/53992.html" rel="external">
          image 6
         </a>
         ). Safety data have demonstrated that individuals with PAVMs that were embolized using metal-containing materials previously designated MRI-incompatible can actually undergo MRI [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Hepatic involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatic involvement occurs in up to two-thirds of patients with HHT [
         <a href="#rid102">
          102-105
         </a>
         ]. As emphasized in guidance from a 2016 document, this is usually silent [
         <a href="#rid106">
          106
         </a>
         ]; however, symptoms can occur and can be improved by appropriate treatments. The potential varying symptoms relate to development of high-output heart failure, portal hypertension, or biliary disease, reflecting different patterns of vascular involvement [
         <a href="#rid107">
          107-109
         </a>
         ]. Large AVMs between the hepatic artery and hepatic vein can cause a significant left-to-right shunt with increased cardiac output that, particularly when combined with anemia, places patients at risk of angina and heart failure [
         <a href="#rid107">
          107,110
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3594.html" rel="external">
          "Hepatic hemangioma"
         </a>
         .)
        </p>
        <p>
         Portal hypertension and hepatic encephalopathy, particularly after episodes of gastrointestinal bleeding, may result both from shunts between the hepatic artery and portal vein, and from increased sinusoidal blood flow, leading to enhanced deposition of fibrous tissue and pseudocirrhosis of the liver [
         <a href="#rid107">
          107,111
         </a>
         ].
        </p>
        <p>
         In our experience, hepatic AVMs affect approximately 50 percent of HHT patients; they are usually silent and not associated with abnormal liver function tests, hepatomegaly or liver bruit. The diagnosis can be established noninvasively by Doppler ultrasonography, CT, or MRI. [
         <a href="#rid112">
          112
         </a>
         ]. Liver biopsy is not recommended as it is not useful in the diagnosis of HHT and may be complicated by bleeding [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
         The natural history of hepatic AVMs was studied in 154 patients with HHT and hepatic vascular malformations who were followed over a median period of 44 months (range: 12 to 181 months) [
         <a href="#rid113">
          113
         </a>
         ]. Eight (5.2 percent) died from vascular malformation-related complications and 39 (25.3 percent) experienced nonfatal complications. The average incidence rates of death and complications were 1.1 and 3.6 per 100 person-years, respectively, while the rate of complete response to therapy was 63 percent.
        </p>
        <p>
         The Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia (2020) provided new recommendations for the management of hepatic AVMs [
         <a href="#rid56">
          56
         </a>
         ]. Diagnostic testing is recommended in patients with symptoms or signs suggestive of complicated liver AVMs (including heart failure, pulmonary hypertension, abnormal cardiac biomarkers, abnormal liver function tests, abdominal pain, portal hypertension, or encephalopathy), with high agreement among experts. There was lower agreement (84 percent) for a recommendation to screen all asymptomatic patients, and expert involvement is recommended in these cases [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         Additionally, estimation of patients’ prognoses using predictors for liver AVMs is recommended to identify those in need of closer monitoring; management is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions", section on 'Hepatic AVMs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1398318828">
         <span class="h2">
          Iron deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epistaxis commonly causes iron deficiency and sequelae due to generation of hemorrhage-adjusted iron requirements (HAIR) that cannot be met through diet alone [
         <a href="#rid114">
          114
         </a>
         ]. A much smaller proportion of individuals develop iron deficiency anemia due to gastrointestinal bleeding.
        </p>
        <p>
         Screening and management was reviewed in detail in the Second International Guidelines for the Diagnosis and Management of HHT [
         <a href="#rid56">
          56
         </a>
         ]. The approach to managing anemia in this HHT, which is characterized by severe continuing blood losses, differs from the management of anemia in many other settings.
        </p>
        <p>
         It was recommended that all adults with HHT and any children with recurrent bleeding or symptoms of anemia should be tested for anemia and iron deficiency; that initial treatment of iron deficiency and anemia should be with oral iron (which has been shown to increase hemoglobin in HHT patients, even at modest doses [
         <a href="#rid115">
          115
         </a>
         ]); and that intravenous iron is recommended where oral iron is not effective, not absorbed/tolerated, or where patients are presenting with severe anemia [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         Management of iron deficiency is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions", section on 'Iron deficiency and iron deficiency anemia'
         </a>
         .)
        </p>
        <p>
         It is important to emphasize that anemia in HHT may be enhanced by other conditions, with the most common exacerbators in our experience being:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Menorrhagia [
         <a href="#rid114">
          114
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intercurrent infection and/or inflammation preventing iron absorption, along with iron-poor diets [
         <a href="#rid116">
          116
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low grade hemolysis [
         <a href="#rid36">
          36,117
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24974364">
         <span class="h2">
          Pulmonary hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary hypertension is not a single disease entity; as in the general population, it can result from multiple causes in people who also have HHT. That said, pulmonary hypertension in HHT is usually due to increased pulmonary flow due to systemic AVMs and/or anemia [
         <a href="#rid118">
          118,119
         </a>
         ]. However, it may be due to a pure pulmonary arterial hypertension (PAH) phenotype indistinguishable from PAH in the general population [
         <a href="#rid119">
          119
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12131106">
         <span class="h2">
          Venous thromboembolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HHT are at increased risk of VTE, the management of which can be compounded by other aspects of their HHT, as clinicians often consider (incorrectly) that treatment or prophylaxis with anticoagulants is contraindicated in HHT [
         <a href="#rid56">
          56,120,121
         </a>
         ]. The Second HHT International Guidelines recommended with high agreement among experts that HHT patients receive anticoagulation (prophylactic or therapeutic) or antiplatelet therapy where there is an indication, with consideration of their individualized risks, and that bleeding in HHT is not an absolute contraindication for these therapies [
         <a href="#rid56">
          56
         </a>
         ]. Data from the European Reference Network suggest that heparin and
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         remain the agents of choice [
         <a href="#rid122">
          122
         </a>
         ].
        </p>
        <p>
         In a study of 609 patients with HHT recruited prospectively in two separate series at a single center, low serum iron levels, attributed to inadequate replacement of hemorrhagic iron losses, were associated with elevated plasma levels of coagulation factor VIII and an increased VTE risk [
         <a href="#rid123">
          123
         </a>
         ]. Management of VTE in individuals with HHT is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs", section on 'Individuals who require anticoagulation (VTE and AF)'
         </a>
         .)
        </p>
        <p>
         In each series, there was an inverse association between factor VIII levels and serum iron that persisted after adjustment for age, inflammation, and/or von Willebrand factor. Low serum iron levels were also associated with VTE: the age-adjusted odds ratio (OR) of 0.91 (95% CI 0.86-0.97) per 1 micromol/L increase in serum iron implied a 2.5-fold increase in VTE risk for a serum iron of 6 micromol/L compared with the mid-normal range (17 micromol/L). The association appeared to depend upon factor VIII levels, as once adjusted for factor VIII levels, the association between VTE and iron was no longer evident.
        </p>
        <p class="headingAnchor" id="H3839692">
         <span class="h2">
          Arterial thromboses and platelets
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iron deficiency is also emerging as a strong risk factor for ischemic stroke in HHT patients with PAVMs. In a series of 497 consecutive patients with HHT and CT-proven PAVMs, the risk of stroke decreased as serum iron increased (adjusted OR 0.96 per mg/mL increase in serum iron; 95% CI 0.92-1.00) [
         <a href="#rid91">
          91
         </a>
         ]. The actual platelet count did not differ in patients with and without strokes. This finding means that for the same PAVMs, the stroke risk would approximately double with serum iron 6 micromol/L compared with mid-normal range (eg, 7 to 27 micromol/L) [
         <a href="#rid91">
          91
         </a>
         ]. This study in HHT patients confirmed data from the 1970s in non-HHT patients that iron deficiency is also associated with enhanced platelet aggregation in response to 5-hydroxytryptamine (5HT) [
         <a href="#rid124">
          124
         </a>
         ]. Importantly, the Second International Guidelines for HHT recommend avoiding the use of dual antiplatelet therapy and anticoagulation where possible in HHT [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3839749">
         <span class="h2">
          Migraines
         </span>
         <span class="headingEndMark">
          —
         </span>
         Migraines are more common in HHT patients than in patients without HHT [
         <a href="#rid125">
          125-127
         </a>
         ]. Migraine features and precipitants appear indistinguishable from migraines in the general population [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
         Multiple studies demonstrate that the risk of migraine in HHT patients is approximately doubled by the presence of PAVMs, and there is evidence that migraines improve following PAVM treatment [
         <a href="#rid78">
          78,96,98,127-129
         </a>
         ]. (See
         <a class="local">
          'Pulmonary AVMs'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3840081">
         <span class="h2">
          Cancer frequency
         </span>
         <span class="headingEndMark">
          —
         </span>
         The frequency of various cancer types in patients with HHT versus controls has been studied. A survey of cancer frequency in patients with HHT over 60 years and age-matched controls showed that despite the predisposition to gastrointestinal cancers conferred by
         <em>
          SMAD4
         </em>
         mutation in some patients, age-adjusted rates of cancer were similar in individuals with HHT versus controls (OR 1.04, 95% CI 0.90-1.21) [
         <a href="#rid130">
          130
         </a>
         ]. Evaluation of common cancer types revealed a lower incidence of lung cancer (OR 0.48, 95% CI 0.30-0.70); an increase in early-onset but fewer late-onset colorectal cancers; no difference in prostate cancer; and a higher incidence of breast cancer (OR 1.52, 95% CI 1.07-2.14). The increase in breast cancer was speculatively attributed to thoracic radiation exposure. A subsequent study of 246 PAVM patients demonstrated that protocols for diagnosis, treatment, and follow-up result in levels of radiation exposure that would be classified as harmful, particularly in patients with underlying HHT; the mean cumulative effective dose (CED) of radiation over an 11-year period was 51.7mSv, and in 26 patients, CED exceeded 100mSv [
         <a href="#rid131">
          131
         </a>
         ]. CT scans accounted for 46 percent of the CED, and interventional procedures accounted for 51 percent.
        </p>
        <p class="headingAnchor" id="H323011">
         <span class="h2">
          Laboratory findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine coagulation and platelet counts are usually normal in HHT.
        </p>
        <p>
         Iron deficiency is the most common finding, especially in those with insufficient iron supplementation. Iron deficiency may be found in people with or without anemia, depending on whether there is a concurrent polycythemic drive due to PAVM-induced hypoxemia. A comparison of red cell indices in HHT patients compared with controls (healthy blood donors) noted a dramatic increase in anemia in the HHT patients [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         In people with HHT, iron deficiency is associated with marginal increases in platelet counts, as seen in the general population, though the platelet count exceeded 400,000/microL in only 35 of 465 individuals (7.5 percent) and exceeded 500,000/microL in only 7 individuals (1.5 percent), and there was no association with ischemic stroke. Iron deficiency is also associated with elevated factor VIII levels and a shortened activated partial thromboplastin time (aPTT) [
         <a href="#rid91">
          91,132
         </a>
         ]; these findings are associated with an increased prevalence of VTE [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         HHT may be diagnosed clinically (using three or more Curaçao Criteria (see
         <a class="local">
          'Consensus criteria'
         </a>
         below)), or by documentation of a pathogenic or likely pathogenic variant in an HHT gene. (See
         <a class="local">
          'Genetic testing'
         </a>
         below.)
        </p>
        <p>
         The Second International Guidelines on HHT recommend making (or excluding) the diagnosis using the Curaçao criteria and/or identifying pathogenic variant in one of the HHT genes [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HHT can be diagnosed clinically with confidence, particularly if there is a first-degree relative with HHT, even when an HHT gene variant has not been identified in the family. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HHT can be excluded with relative confidence if a known familial pathogenic variant is not present in the individual, taking into account the exact variant subtype.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of HHT clinical features does not preclude a diagnosis of HHT as shown by genetic studies [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of an HHT causal variant does not preclude a diagnosis of HHT unless the causal gene in that family has already been identified in a preceding generation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When the individual is the first affected ("founder") member of the family, mosaicism may be present [
         <a href="#rid37">
          37-39
         </a>
         ]; this can pose challenges for molecular testing [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A child of a parent with HHT should be considered to have possible HHT unless the disorder is excluded by genetic testing for the known familial variant.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Consensus criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         International consensus diagnostic criteria (the Curaçao diagnostic criteria) are based upon the following four findings [
         <a href="#rid133">
          133,134
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spontaneous and recurrent epistaxis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple mucocutaneous telangiectasia at characteristic sites
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Visceral involvement (eg, gastrointestinal telangiectasia; pulmonary, cerebral, or hepatic arteriovenous malformations [AVMs])
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A first-degree relative with HHT
        </p>
        <p>
        </p>
        <p>
         These criteria define "definite" (three or four criteria), "suspected" (two criteria), and "unlikely" (zero or one criterion). These have been validated by molecular studies; in probands who met the strictly applied criteria in an HHT Center of Excellence, 137 of 141 (97.2 percent) were found to have a pathogenic variant in either
         <em>
          ENG
         </em>
         (66 of 141 [46.8 percent]),
         <em>
          ACVRL1
         </em>
         (69 of 141 [48.9 percent]), or
         <em>
          SMAD4
         </em>
         (2 of 141 [2.8 percent]) [
         <a href="#rid135">
          135
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1073859589">
         <span class="h2">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis may be established or confirmed by identification of a pathogenic sequence variant in
         <em>
          ENG
         </em>
         ,
         <em>
          ACVRL1
         </em>
         ,
         <em>
          SMAD4
         </em>
         , or
         <em>
          GDF2
         </em>
         . Although this is not required to make a diagnosis of HHT, the Second International Guidelines suggest genetic testing for all individuals with HHT, as it may facilitate family testing and additional evaluations (eg, screening colonoscopies for individuals with pathogenic variants in the
         <em>
          SMAD4
         </em>
         gene) [
         <a href="#rid56">
          56
         </a>
         ]. Genetic testing can also be used to establish the diagnosis in individuals with suspected HHT who do not meet clinical criteria. (See
         <a class="local">
          'Consensus criteria'
         </a>
         above.)
        </p>
        <p>
         Genetic testing does not detect all variants that might be present, and care is required not to over-interpret sequence variants that are not disease-causing. Detailed discussions for HHT are provided within the context of the American College of Medical Genetics and Genomics (ACMG) guidance and current databases [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Multiple centers for genetic testing are available in different countries. Previously reported variants (including pathogenic, likely pathogenic, benign, likely benign, and variants of unknown significance [VUSs]/pending classification) are registered on the HHT mutation database, available at
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Farup.utah.edu%2Fdatabase%2FHHT%2F&amp;token=EhO1sIjRC%2BQY0lbH%2FIIl%2B6RI2dgjzAAgMCcP1rNIiIv1uS91N%2BFcn2yE%2Bi3fdKg7&amp;TOPIC_ID=1345" target="_blank">
          http://arup.utah.edu/database/HHT/
         </a>
         [
         <a href="#rid136">
          136
         </a>
         ] and on ClinVar [
         <a href="#rid137">
          137
         </a>
         ]. A more general discussion of variant classification and determination of significance is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/96539.html" rel="external">
          "Secondary findings from genetic testing", section on 'Definitions and classification of variants'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12130735">
         <span class="h1">
          RESOURCES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Educational materials for patients with HHT and the location of specialized centers for diagnosing and managing HHT and pulmonary arteriovenous malformations (PAVMs) are available from
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fcurehht.org%2F&amp;token=a7%2FGN7K9S0SGpcQnma44kR3Syk%2BNVaQ%2Bv9WECcchB%2B8%3D&amp;TOPIC_ID=1345" target="_blank">
          Cure HHT
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvascern.eu%2Fexpertise%2Frare-diseases-wgs%2Fhht-wg%2F&amp;token=VVq4MOGhA8xc7GYzTpiZNi47aji3yU7jI3qhjgaDI%2B65yNitCixg6te3pHzT465ASOUbGTgUTkHvs358fl34aQ%3D%3D&amp;TOPIC_ID=1345" target="_blank">
          VASCERN HHT
         </a>
         , and other patient groups.
        </p>
        <p>
         Additional information is available online:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Introduction to HHT from VASCERN HHT –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3D0YjWf7Agn40%26feature%3Dyoutu.be&amp;token=3BBziCZQDrEhIlt93szQloH6eZnp6PMXkxC7JnVMP%2FVwyhINljBULIPcoYuw6eR%2BzwUnFCU8r75PJTne6GFOF2bFKN4qExBHddGYV6pNLxw%3D&amp;TOPIC_ID=1345" target="_blank">
          https://www.youtube.com/watch?v=0YjWf7Agn40&amp;feature=youtu.be
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Overview of HHT –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3Dz2gALD8xSNE%26feature%3Dyoutu.be&amp;token=3BBziCZQDrEhIlt93szQloH6eZnp6PMXkxC7JnVMP%2FWDHjF6C0Y9n85RVR1%2FhrR6AvbmVynkInFAMN3K3ojIXI9ftUWkm4DG8sNK0rpGYF4%3D&amp;TOPIC_ID=1345" target="_blank">
          https://www.youtube.com/watch?v=z2gALD8xSNE&amp;feature=youtu.be
         </a>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2172291441">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119057.html" rel="external">
          "Society guideline links: Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence
         </strong>
         – Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder with a clinical prevalence of 1:5000 to 1:8000. The true prevalence is likely to be higher in view of the paucity of clinical symptoms present in genetically-confirmed individuals diagnosed based on other presentations. Many individuals with HHT are unaware of their disease. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology
         </strong>
         – All HHT genes encode proteins involved in bone morphogenetic protein (BMP) signalling, most commonly
         <em>
          ENG
         </em>
         (encodes endoglin) and
         <em>
          ACVRL1
         </em>
         (encodes ALK1). Rarer causes are
         <em>
          SMAD4
         </em>
         , which is important to identify because haploinsufficiency also results in juvenile polyposis syndrome requiring additional screening, and
         <em>
          GDF2
         </em>
         , which is rare and has an increased association with pulmonary hypertension.
         <em>
         </em>
         Pathogenic variants in these genes perturb vascular remodeling and disrupt blood vessel wall integrity. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Patients with HHT may be asymptomatic or have a wide spectrum of clinical manifestations. Overall life expectancy is normal with appropriate management, but there can be life-limiting complications, and these subgroups are the ones most familiar to hospital clinicians. As summarized in the Consensus Orphanet statement from the European Reference Network, the most common signs include epistaxis, cutaneous or mucosal telangiectasia, anemia, and complications of visceral arteriovenous malformations (AVMs). The age of onset of AVM complications varies from childhood to older adulthood. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pulmonary
         </strong>
         – Pulmonary AVMs (PAVMs) may manifest with brain abscess, stroke, transient ischemic attack, chronic hypoxemia, or rarely, hemorrhagic rupture.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          CNS
         </strong>
         – Central nervous system (CNS) AVMs can bleed, or rarely cause symptoms of compression.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hepatic
         </strong>
         – Hepatic AVMs can remain latent; in a limited number of individuals, they can lead to high output cardiac failure, portal hypertension, pulmonary hypertension, or ischemic cholangitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Gastrointestinal
         </strong>
         – Gastrointestinal telangiectasia increase with age and can worsen anemia due to chronic blood loss.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – HHT may be diagnosed clinically (using three or more Curaçao Criteria) or by genetic testing showing a pathogenic or likely pathogenic variant in an HHT gene. (See
         <a class="local">
          'Genetic testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The following four international consensus criteria define "definite HHT" (three to four criteria present), "suspected HHT" (two criteria), and "unlikely HHT" (zero or one criterion). (see
         <a class="local">
          'Consensus criteria'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Spontaneous and recurrent nosebleeds
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Multiple mucocutaneous telangiectasia at characteristic sites
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Visceral involvement (gastrointestinal, pulmonary, cerebral, or hepatic AVMs)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A first-degree relative with HHT
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Management of HHT is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H583517746">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Vijeya Ganesan, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bideau A, Plauchu H, Brunet G, Robert J. Epidemiological investigation of Rendu-Osler disease in France: its geographical distribution and prevalence. Popul 1989; 44:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dakeishi M, Shioya T, Wada Y, et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat 2002; 19:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med 1999; 245:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westermann CJ, Rosina AF, De Vries V, de Coteau PA. The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: a family screening. Am J Med Genet A 2003; 116A:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shovlin CL, Buscarini E, Kjeldsen AD, et al. European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT). Orphanet J Rare Dis 2018; 13:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donaldson JW, McKeever TM, Hall IP, et al. The UK prevalence of hereditary haemorrhagic telangiectasia and its association with sex, socioeconomic status and region of residence: a population-based study. Thorax 2014; 69:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shovlin CL, Jackson JE, Bamford KB, et al. Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Thorax 2008; 63:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shovlin CL, Simeoni I, Downes K, et al. Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia. Blood 2020; 136:1907.
          </a>
         </li>
         <li class="breakAll">
          McDonald J, Stevenson DA. Hereditary hemorrhagic telangiectasia. In: GeneReviews® [Internet], Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A. (Eds), University of Washington, Seattle, Seattle (WA) 2000.
         </li>
         <li class="breakAll">
          HHT Mutation Database. ARUP Laboratories and the University of Utah. Available at: https://arup.utah.edu/database/HHT/ (Accessed on December 21, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006; 43:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009; 17:860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balachandar S, Graves TJ, Shimonty A, et al. Identification and validation of a novel pathogenic variant in GDF2 (BMP9) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations. Am J Med Genet A 2022; 188:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farhan A, Yuan F, Partan E, Weiss CR. Clinical manifestations of patients with GDF2 mutations associated with hereditary hemorrhagic telangiectasia type 5. Am J Med Genet A 2022; 188:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu J, Yang J, Tang X, et al. Homozygous GDF2-Related Hereditary Hemorrhagic Telangiectasia in a Chinese Family. Pediatrics 2020; 146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wooderchak-Donahue WL, McDonald J, O'Fallon B, et al. BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am J Hum Genet 2013; 93:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodgson J, Ruiz-Llorente L, McDonald J, et al. Homozygous GDF2 nonsense mutations result in a loss of circulating BMP9 and BMP10 and are associated with either PAH or an "HHT-like" syndrome in children. Mol Genet Genomic Med 2021; 9:e1685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernandez F, Huether R, Carter L, et al. Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia. Hum Genome Var 2015; 2:15040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bayrak-Toydemir P, McDonald J, Akarsu N, et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A 2006; 140:2155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Hajjam M, Mekki A, Palmyre A, et al. RASA1 phenotype overlaps with hereditary haemorrhagic telangiectasia: two case reports. J Med Genet 2021; 58:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wooderchak-Donahue WL, Akay G, Whitehead K, et al. Phenotype of CM-AVM2 caused by variants in EPHB4: how much overlap with hereditary hemorrhagic telangiectasia (HHT)? Genet Med 2019; 21:2007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald J, Bayrak-Toydemir P, DeMille D, et al. Curaçao diagnostic criteria for hereditary hemorrhagic telangiectasia is highly predictive of a pathogenic variant in ENG or ACVRL1 (HHT1 and HHT2). Genet Med 2020; 22:1201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mirshahi UL, Colclough K, Wright CF, et al. Reduced penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected cohorts. Am J Hum Genet 2022; 109:2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson E, Sharma L, Alsafi A, Shovlin CL. Pulmonary arteriovenous malformations may be the only clinical criterion present in genetically confirmed hereditary haemorrhagic telangiectasia. Thorax 2022; 77:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjeldsen AD, Møller TR, Brusgaard K, et al. Clinical symptoms according to genotype amongst patients with hereditary haemorrhagic telangiectasia. J Intern Med 2005; 258:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Letteboer TG, Mager JJ, Snijder RJ, et al. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet 2006; 43:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabbà C, Pasculli G, Lenato GM, et al. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost 2007; 5:1149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesca G, Olivieri C, Burnichon N, et al. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genet Med 2007; 9:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bossler AD, Richards J, George C, et al. Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype. Hum Mutat 2006; 27:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kilian A, Latino GA, White AJ, et al. Genotype-Phenotype Correlations in Children with HHT. J Clin Med 2020; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benzinou M, Clermont FF, Letteboer TG, et al. Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nat Commun 2012; 3:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Letteboer TG, Benzinou M, Merrick CB, et al. Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14. Front Genet 2015; 6:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pawlikowska L, Nelson J, Guo DE, et al. The ACVRL1 c.314-35A&gt;G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations. Am J Med Genet A 2015; 167:1262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawasaki K, Freimuth J, Meyer DS, et al. Genetic variants of Adam17 differentially regulate TGFβ signaling to modify vascular pathology in mice and humans. Proc Natl Acad Sci U S A 2014; 111:7723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joyce KE, Onabanjo E, Brownlow S, et al. Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation. Blood Adv 2022; 6:3956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Best DH, Vaughn C, McDonald J, et al. Mosaic ACVRL1 and ENG mutations in hereditary haemorrhagic telangiectasia patients. J Med Genet 2011; 48:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee NP, Matevski D, Dumitru D, et al. Identification of clinically relevant mosaicism in type I hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tørring PM, Kjeldsen AD, Ousager LB, Brusgaard K. ENG mutational mosaicism in a family with hereditary hemorrhagic telangiectasia. Mol Genet Genomic Med 2018; 6:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald J, Wooderchak-Donahue WL, Henderson K, et al. Tissue-specific mosaicism in hereditary hemorrhagic telangiectasia: Implications for genetic testing in families. Am J Med Genet A 2018; 176:1618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarke JM, Alikian M, Xiao S, et al. Low grade mosaicism in hereditary haemorrhagic telangiectasia identified by bidirectional whole genome sequencing reads through the 100,000 Genomes Project clinical diagnostic pipeline. J Med Genet 2020; 57:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Govani FS, Giess A, Mollet IG, et al. Directional next-generation RNA sequencing and examination of premature termination codon mutations in endoglin/hereditary haemorrhagic telangiectasia. Mol Syndromol 2013; 4:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snellings DA, Gallione CJ, Clark DS, et al. Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1. Am J Hum Genet 2019; 105:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saito T, Bokhove M, Croci R, et al. Structural Basis of the Human Endoglin-BMP9 Interaction: Insights into BMP Signaling and HHT1. Cell Rep 2017; 19:1917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertolino P, Deckers M, Lebrin F, ten Dijke P. Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 2005; 128:585S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bailly S. HHT is not a TGF-beta disease. Blood 2008; 111:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eker OF, Boccardi E, Sure U, et al. European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT). Orphanet J Rare Dis 2020; 15:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourdeau A, Cymerman U, Paquet ME, et al. Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1. Am J Pathol 2000; 156:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999; 104:1343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gu Y, Jin P, Zhang L, et al. Functional analysis of mutations in the kinase domain of the TGF-beta receptor ALK1 reveals different mechanisms for induction of hereditary hemorrhagic telangiectasia. Blood 2006; 107:1951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urness LD, Sorensen LK, Li DY. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 2000; 26:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park SO, Lee YJ, Seki T, et al. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 2008; 111:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005; 90:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gkatzis K, Thalgott J, Dos-Santos-Luis D, et al. Interaction Between ALK1 Signaling and Connexin40 in the Development of Arteriovenous Malformations. Arterioscler Thromb Vasc Biol 2016; 36:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faughnan ME, Mager JJ, Hetts SW, et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med 2020; 173:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le TTT, Martinent G, Dupuis-Girod S, et al. Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT. Orphanet J Rare Dis 2022; 17:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasthuri RS, Chaturvedi S, Thomas S, et al. Development and performance of a hereditary hemorrhagic telangiectasia-specific quality-of-life instrument. Blood Adv 2022; 6:4301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haitjema T, Disch F, Overtoom TT, et al. Screening family members of patients with hereditary hemorrhagic telangiectasia. Am J Med 1995; 99:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cottin V, Plauchu H, Bayle JY, et al. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med 2004; 169:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Gent MW, Post MC, Snijder RJ, et al. Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography study. Chest 2010; 138:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fulbright RK, Chaloupka JC, Putman CM, et al. MR of hereditary hemorrhagic telangiectasia: prevalence and spectrum of cerebrovascular malformations. AJNR Am J Neuroradiol 1998; 19:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brinjikji W, Iyer VN, Yamaki V, et al. Neurovascular Manifestations of Hereditary Hemorrhagic Telangiectasia: A Consecutive Series of 376 Patients during 15 Years. AJNR Am J Neuroradiol 2016; 37:1479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallitelli M, Pasculli G, Fiore T, et al. Emergencies in hereditary haemorrhagic telangiectasia. QJM 2006; 99:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shovlin CL, Buscarini E, Sabbà C, et al. The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care. Eur J Med Genet 2022; 65:104370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dupuis-Girod S, Bailly S, Plauchu H. Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. J Thromb Haemost 2010; 8:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010; 24:203.
          </a>
         </li>
         <li class="breakAll">
          https://www.orpha.net/consor/www/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=774 (Accessed on September 18, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giordano P, Lenato GM, Suppressa P, et al. Hereditary hemorrhagic telangiectasia: arteriovenous malformations in children. J Pediatr 2013; 163:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shovlin CL, Awan I, Cahilog Z, et al. Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction. Int J Cardiol 2016; 215:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plauchu H, de Chadarévian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Latino GA, Al-Saleh S, Alharbi N, et al. Prevalence of pulmonary arteriovenous malformations in children versus adults with hereditary hemorrhagic telangiectasia. J Pediatr 2013; 163:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krings T, Ozanne A, Chng SM, et al. Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years. Neuroradiology 2005; 47:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabbà C, Pasculli G, Suppressa P, et al. Life expectancy in patients with hereditary haemorrhagic telangiectasia. QJM 2006; 99:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjeldsen A, Aagaard KS, Tørring PM, et al. 20-year follow-up study of Danish HHT patients-survival and causes of death. Orphanet J Rare Dis 2016; 11:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Gussem EM, Kroon S, Hosman AE, et al. Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence. J Clin Med 2020; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva BM, Hosman AE, Devlin HL, Shovlin CL. Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia. Laryngoscope 2013; 123:1092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elphick A, Shovlin CL. Relationships between epistaxis, migraines, and triggers in hereditary hemorrhagic telangiectasia. Laryngoscope 2014; 124:1521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoag JB, Terry P, Mitchell S, et al. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 2010; 120:838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karnezis TT, Davidson TM. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011; 121:636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjeldsen AD, Kjeldsen J. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2000; 95:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasculli G, Quaranta D, Lenato GM, et al. Capillaroscopy of the dorsal skin of the hands in hereditary hemorrhagic telangiectasia. QJM 2005; 98:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bharatha A, Faughnan ME, Kim H, et al. Brain arteriovenous malformation multiplicity predicts the diagnosis of hereditary hemorrhagic telangiectasia: quantitative assessment. Stroke 2012; 43:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacout A, Pelage JP, Lesur G, et al. Pancreatic involvement in hereditary hemorrhagic telangiectasia: assessment with multidetector helical CT. Radiology 2010; 254:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gefen AM, White AJ. Asymptomatic pulmonary arteriovenous malformations in children with hereditary hemorrhagic telangiectasia. Pediatr Pulmonol 2017; 52:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gawecki F, Strangeways T, Amin A, et al. Exercise capacity reflects airflow limitation rather than hypoxaemia in patients with pulmonary arteriovenous malformations. QJM 2019; 112:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gawecki F, Myers J, Shovlin CL. Veterans Specific Activity Questionnaire (VSAQ): a new and efficient method of assessing exercise capacity in patients with pulmonary arteriovenous malformations. BMJ Open Respir Res 2019; 6:e000351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shovlin C, Bamford K, Wray D. Post-NICE 2008: Antibiotic prophylaxis prior to dental procedures for patients with pulmonary arteriovenous malformations (PAVMs) and hereditary haemorrhagic telangiectasia. Br Dent J 2008; 205:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Topiwala KK, Patel SD, Saver JL, et al. Ischemic Stroke and Pulmonary Arteriovenous Malformations: A Review. Neurology 2022; 98:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shovlin CL, Chamali B, Santhirapala V, et al. Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: associations with iron deficiency and platelets. PLoS One 2014; 9:e88812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Topiwala KK, Patel SD, Pervez M, et al. Ischemic Stroke in Patients With Pulmonary Arteriovenous Fistulas. Stroke 2021; 52:e311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alsafi A, Jackson JE, Fatania G, et al. Patients with in-situ metallic coils and Amplatzer vascular plugs used to treat pulmonary arteriovenous malformations since 1984 can safely undergo magnetic resonance imaging. Br J Radiol 2019; 92:20180752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boother EJ, Brownlow S, Tighe HC, et al. Cerebral Abscess Associated With Odontogenic Bacteremias, Hypoxemia, and Iron Loading in Immunocompetent Patients With Right-to-Left Shunting Through Pulmonary Arteriovenous Malformations. Clin Infect Dis 2017; 65:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shovlin CL, Sodhi V, McCarthy A, et al. Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): suggested approach for obstetric services. BJOG 2008; 115:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Post MC, Letteboer TG, Mager JJ, et al. A pulmonary right-to-left shunt in patients with hereditary hemorrhagic telangiectasia is associated with an increased prevalence of migraine. Chest 2005; 128:2485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel T, Elphick A, Jackson JE, Shovlin CL. Injections of Intravenous Contrast for Computerized Tomography Scans Precipitate Migraines in Hereditary Hemorrhagic Telangiectasia Subjects at Risk of Paradoxical Emboli: Implications for Right-to-Left Shunt Risks. Headache 2016; 56:1659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Post MC, Thijs V, Schonewille WJ, et al. Embolization of pulmonary arteriovenous malformations and decrease in prevalence of migraine. Neurology 2006; 66:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stephan MJ, Nesbit GM, Behrens ML, et al. Endovascular treatment of spinal arteriovenous fistula in a young child with hereditary hemorrhagic telangiectasia. Case report. J Neurosurg 2005; 103:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maher CO, Piepgras DG, Brown RD Jr, et al. Cerebrovascular manifestations in 321 cases of hereditary hemorrhagic telangiectasia. Stroke 2001; 32:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohr JP, Parides MK, Stapf C, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet 2014; 383:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piantanida M, Buscarini E, Dellavecchia C, et al. Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HHT1 or HHT2. J Med Genet 1996; 33:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald JE, Miller FJ, Hallam SE, et al. Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred. Am J Med Genet 2000; 93:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buscarini E, Danesino C, Plauchu H, et al. High prevalence of hepatic focal nodular hyperplasia in subjects with hereditary hemorrhagic telangiectasia. Ultrasound Med Biol 2004; 30:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buonamico P, Suppressa P, Lenato GM, et al. Liver involvement in a large cohort of patients with hereditary hemorrhagic telangiectasia: echo-color-Doppler vs multislice computed tomography study. J Hepatol 2008; 48:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           European Association for the Study of the Liver. Electronic address:
           <span class="__cf_email__" data-cfemail="ed888c9e81828b8b848e88ad888c9e81828b8b848e88c38898">
            [email protected]
           </span>
           . EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Tsao G, Korzenik JR, Young L, et al. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2000; 343:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeLeve LD, Valla DC, Garcia-Tsao G, American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009; 49:1729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buscarini E, Plauchu H, Garcia Tsao G, et al. Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. Liver Int 2006; 26:1040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caselitz M, Wagner S, Chavan A, et al. Clinical outcome of transfemoral embolisation in patients with arteriovenous malformations of the liver in hereditary haemorrhagic telangiectasia (Weber-Rendu-Osler disease). Gut 1998; 42:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fogerty RL, Greenwald JL, McDermott S, et al. Case 7-2017. A 73-Year-Old Man with Confusion and Recurrent Epistaxis. N Engl J Med 2017; 376:972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buscarini E, Buscarini L, Civardi G, et al. Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: imaging findings. AJR Am J Roentgenol 1994; 163:1105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buscarini E, Leandro G, Conte D, et al. Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia. Dig Dis Sci 2011; 56:2166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finnamore H, Le Couteur J, Hickson M, et al. Hemorrhage-adjusted iron requirements, hematinics and hepcidin define hereditary hemorrhagic telangiectasia as a model of hemorrhagic iron deficiency. PLoS One 2013; 8:e76516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizvi A, Macedo P, Babawale L, et al. Hemoglobin Is a Vital Determinant of Arterial Oxygen Content in Hypoxemic Patients with Pulmonary Arteriovenous Malformations. Ann Am Thorac Soc 2017; 14:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finnamore HE, Whelan K, Hickson M, Shovlin CL. Top dietary iron sources in the UK. Br J Gen Pract 2014; 64:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thielemans L, Layton DM, Shovlin CL. Low serum haptoglobin and blood films suggest intravascular hemolysis contributes to severe anemia in hereditary hemorrhagic telangiectasia. Haematologica 2019; 104:e127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vorselaars VM, Velthuis S, Snijder RJ, et al. Pulmonary hypertension in hereditary haemorrhagic telangiectasia. World J Cardiol 2015; 7:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girerd B, Montani D, Coulet F, et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010; 181:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaetani E, Agostini F, Porfidia A, et al. Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group. Orphanet J Rare Dis 2019; 14:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devlin HL, Hosman AE, Shovlin CL. Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia. N Engl J Med 2013; 368:876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shovlin CL, Millar CM, Droege F, et al. Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis 2019; 14:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Livesey JA, Manning RA, Meek JH, et al. Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia. Thorax 2012; 67:328.
          </a>
         </li>
         <li class="breakAll">
          Woods HF, Youdim MB, Boulllin D, Callender S. Monoamine metabolism and platelet function in iron-deficiency anaemia. In: Iron metabolism. In CIBA Foundation Symposium 51 (new series), Elsevier, Amsterdam 1977. p.227.
         </li>
         <li>
          <a class="nounderline abstract_t">
           HODGSON CH, BURCHELL HB, GOOD CA, CLAGETT OT. Hereditary hemorrhagic telangiectasia and pulmonary arteriovenous fistula: survey of a large family. N Engl J Med 1959; 261:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steele JG, Nath PU, Burn J, Porteous ME. An association between migrainous aura and hereditary haemorrhagic telangiectasia. Headache 1993; 33:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marziniak M, Jung A, Guralnik V, et al. An association of migraine with hereditary haemorrhagic telangiectasia independently of pulmonary right-to-left shunts. Cephalalgia 2009; 29:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thenganatt J, Schneiderman J, Hyland RH, et al. Migraines linked to intrapulmonary right-to-left shunt. Headache 2006; 46:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Post MC, van Gent MW, Plokker HW, et al. Pulmonary arteriovenous malformations associated with migraine with aura. Eur Respir J 2009; 34:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosman AE, Devlin HL, Silva BM, Shovlin CL. Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls. Orphanet J Rare Dis 2013; 8:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanneman K, Faughnan ME, Prabhudesai V. Cumulative radiation dose in patients with hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations. Can Assoc Radiol J 2014; 65:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shovlin CL, Sulaiman NL, Govani FS, et al. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost 2007; 98:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48:73.
          </a>
         </li>
         <li class="breakAll">
          Mcdonald J, Bayrak-Toydemir P, Whitehead A. Curacao Criteria highly predictive of a mutation in ACVRL1 or ENG. Proceedings of the 11th International HHT Scientific Conference, June 11-14, 2015; p.33.
         </li>
         <li class="breakAll">
          http://arup.utah.edu/database/HHT/ (Accessed on August 29, 2012).
         </li>
         <li class="breakAll">
          https://www.ncbi.nlm.nih.gov/clinvar/ (Accessed on September 18, 2020).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1345 Version 43.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12157905" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Epidemiological investigation of Rendu-Osler disease in France: its geographical distribution and prevalence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11793473" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10095814" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7666879" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12522784" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: a family screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30111344" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24188926" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The UK prevalence of hereditary haemorrhagic telangiectasia and its association with sex, socioeconomic status and region of residence: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17981912" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32573726" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32573726" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32573726" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15879500" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19337313" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Hereditary haemorrhagic telangiectasia: a clinical and scientific review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34904380" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Identification and validation of a novel pathogenic variant in GDF2 (BMP9) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34611981" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clinical manifestations of patients with GDF2 mutations associated with hereditary hemorrhagic telangiectasia type 5.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32669404" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Homozygous GDF2-Related Hereditary Hemorrhagic Telangiectasia in a Chinese Family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23972370" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33834622" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Homozygous GDF2 nonsense mutations result in a loss of circulating BMP9 and BMP10 and are associated with either PAH or an "HHT-like" syndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27081547" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16969873" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32900839" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : RASA1 phenotype overlaps with hereditary haemorrhagic telangiectasia: two case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30760892" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Phenotype of CM-AVM2 caused by variants in EPHB4: how much overlap with hereditary hemorrhagic telangiectasia (HHT)?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32300199" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Curaçao diagnostic criteria for hereditary hemorrhagic telangiectasia is highly predictive of a pathogenic variant in ENG or ACVRL1 (HHT1 and HHT2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36257325" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Reduced penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35165143" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pulmonary arteriovenous malformations may be the only clinical criterion present in genetically confirmed hereditary haemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16164574" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Clinical symptoms according to genotype amongst patients with hereditary haemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16155196" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17388964" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17224686" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16752392" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32842615" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Genotype-Phenotype Correlations in Children with HHT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22233626" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25815003" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25847705" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The ACVRL1 c.314-35A&gt;G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24812125" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Genetic variants of Adam17 differentially regulate TGFβsignaling to modify vascular pathology in mice and humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35316832" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21378382" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Mosaic ACVRL1 and ENG mutations in hereditary haemorrhagic telangiectasia patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21415079" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Identification of clinically relevant mosaicism in type I hereditary haemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29243366" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : ENG mutational mosaicism in a family with hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29736967" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Tissue-specific mosaicism in hereditary hemorrhagic telangiectasia: Implications for genetic testing in families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32303606" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Low grade mosaicism in hereditary haemorrhagic telangiectasia identified by bidirectional whole genome sequencing reads through the 100,000 Genomes Project clinical diagnostic pipeline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23801935" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Directional next-generation RNA sequencing and examination of premature termination codon mutations in endoglin/hereditary haemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31630786" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28564608" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Structural Basis of the Human Endoglin-BMP9 Interaction: Insights into BMP Signaling and HHT1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16373850" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : HHT is not a TGF-beta disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32600364" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10702408" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10562296" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A murine model of hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16282348" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Functional analysis of mutations in the kinase domain of the TGF-beta receptor ALK1 reveals different mechanisms for induction of hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11062473" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Arteriovenous malformations in mice lacking activin receptor-like kinase-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17911384" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9393997" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : TGF-beta signalling from cell membrane to nucleus through SMAD proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15951295" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26821948" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Interaction Between ALK1 Signaling and Connexin40 in the Development of Arteriovenous Malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32894695" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35854330" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35877137" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Development and performance of a hereditary hemorrhagic telangiectasia-specific quality-of-life instrument.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7485210" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Screening family members of patients with hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14742303" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20154077" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9541302" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : MR of hereditary hemorrhagic telangiectasia: prevalence and spectrum of cerebrovascular malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27012295" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Neurovascular Manifestations of Hereditary Hemorrhagic Telangiectasia: A Consecutive Series of 376 Patients during 15 Years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16339212" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Emergencies in hereditary haemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34737116" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20345718" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Hereditary hemorrhagic telangiectasia: from molecular biology to patient care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20870325" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20870325" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23535011" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Hereditary hemorrhagic telangiectasia: arteriovenous malformations in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27116331" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2729347" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23522378" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Prevalence of pulmonary arteriovenous malformations in children versus adults with hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16136265" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16595564" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Life expectancy in patients with hereditary haemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27876060" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : 20-year follow-up study of Danish HHT patients-survival and causes of death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33172103" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23404156" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24458873" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Relationships between epistaxis, migraines, and triggers in hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20087969" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : An epistaxis severity score for hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21344445" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10685743" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16126740" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Capillaroscopy of the dorsal skin of the hands in hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22034007" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Brain arteriovenous malformation multiplicity predicts the diagnosis of hereditary hemorrhagic telangiectasia: quantitative assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20093519" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Pancreatic involvement in hereditary hemorrhagic telangiectasia: assessment with multidetector helical CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28608633" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Asymptomatic pulmonary arteriovenous malformations in children with hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10413726" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30657990" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Exercise capacity reflects airflow limitation rather than hypoxaemia in patients with pulmonary arteriovenous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30956797" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Veterans Specific Activity Questionnaire (VSAQ): a new and efficient method of assessing exercise capacity in patients with pulmonary arteriovenous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19023305" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Post-NICE 2008: Antibiotic prophylaxis prior to dental procedures for patients with pulmonary arteriovenous malformations (PAVMs) and hereditary haemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34880092" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Ischemic Stroke and Pulmonary Arteriovenous Malformations: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24586400" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: associations with iron deficiency and platelets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34082575" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Ischemic Stroke in Patients With Pulmonary Arteriovenous Fistulas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30894022" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Patients with in-situ metallic coils and Amplatzer vascular plugs used to treat pulmonary arteriovenous malformations since 1984 can safely undergo magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28430880" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Cerebral Abscess Associated With Odontogenic Bacteremias, Hypoxemia, and Iron Loading in Immunocompetent Patients With Right-to-Left Shunting Through Pulmonary Arteriovenous Malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18518871" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): suggested approach for obstetric services.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16236913" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : A pulmonary right-to-left shunt in patients with hereditary hemorrhagic telangiectasia is associated with an increased prevalence of migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27727478" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Injections of Intravenous Contrast for Computerized Tomography Scans Precipitate Migraines in Hereditary Hemorrhagic Telangiectasia Subjects at Risk of Paradoxical Emboli: Implications for Right-to-Left Shunt Risks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16434654" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Embolization of pulmonary arteriovenous malformations and decrease in prevalence of migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16302622" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Endovascular treatment of spinal arteriovenous fistula in a young child with hereditary hemorrhagic telangiectasia. Case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11283386" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Cerebrovascular manifestations in 321 cases of hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24268105" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8782041" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HHT1 or HHT2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10946360" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15550313" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : High prevalence of hepatic focal nodular hyperplasia in subjects with hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18321607" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Liver involvement in a large cohort of patients with hereditary hemorrhagic telangiectasia: echo-color-Doppler vs multislice computed tomography study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26516032" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : EASL Clinical Practice Guidelines: Vascular diseases of the liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11006369" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Liver disease in patients with hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19399912" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Vascular disorders of the liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17032403" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9505897" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Clinical outcome of transfemoral embolisation in patients with arteriovenous malformations of the liver in hereditary haemorrhagic telangiectasia (Weber-Rendu-Osler disease).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28273029" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Case 7-2017. A 73-Year-Old Man with Confusion and Recurrent Epistaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7976883" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: imaging findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21290179" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24146883" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Hemorrhage-adjusted iron requirements, hematinics and hepcidin define hereditary hemorrhagic telangiectasia as a model of hemorrhagic iron deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28267932" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Hemoglobin Is a Vital Determinant of Arterial Oxygen Content in Hypoxemic Patients with Pulmonary Arteriovenous Malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24686867" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Top dietary iron sources in the UK.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30337360" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Low serum haptoglobin and blood films suggest intravascular hemolysis contributes to severe anemia in hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26015855" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Pulmonary hypertension in hereditary haemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20056902" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31878955" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23445111" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31462308" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22169361" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22169361" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14402245" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Hereditary hemorrhagic telangiectasia and pulmonary arteriovenous fistula: survey of a large family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8486513" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : An association between migrainous aura and hereditary haemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18771488" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : An association of migraine with hereditary haemorrhagic telangiectasia independently of pulmonary right-to-left shunts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16618261" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Migraines linked to intrapulmonary right-to-left shunt.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19324948" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Pulmonary arteriovenous malformations associated with migraine with aura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24354965" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23927890" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Cumulative radiation dose in patients with hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18000608" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10751092" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19553198" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
